
    
      TAK-085 is an oral capsule medicine licensed to Takeda Pharmaceutical Company Ltd. TAK-085
      contains omega-3 fatty acid ethyl (mainly, ethyl eicosapentaenoate (EPA-E) and ethyl
      docosahexaenoic acid (DHA-E)).

      This is a phase 3, double-blind, randomized study to evaluate the efficacy and safety of
      TAK-085 compared to EPA-E in participants with hypertriglyceridemia who are undergoing
      lifestyle modification.

      The study period is a total of 20 weeks, comprised of an 8- week screening period and 12
      weeks of treatment.
    
  